Vivos Therapeutics, Inc.
2.6700+0.07 (+2.69%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · VVOS · USD
Key Stats
Market Cap
20.04MP/E (TTM)
-Basic EPS (TTM)
-1.16Dividend Yield
0%Recent Filings
8-K
Expands ATM stock offering
Vivos Therapeutics filed a prospectus supplement on October 24, 2025, to boost the aggregate offering price for shares issuable under its February 14, 2025, At The Market Offering Agreement with H.C. Wainwright & Co. This adjustment expands potential capital raising through common stock sales. Legal opinion from Ellenoff Grossman & Schole LLP confirms the shares' validity. No specific offering amount or proceeds use disclosed.
8-K
Pediatric OSA treatment breakthrough
Vivos Therapeutics announced peer-reviewed data from a multicenter trial showing its DNA appliance safely and effectively treats pediatric obstructive sleep apnea, with 77% of participants achieving at least 50% severity reduction and average airway volume increasing 67.8%. This non-surgical alternative challenges invasive adenotonsillectomy, which succeeds in only 20-40% of cases. Data bolsters Vivos' C.A.R.E. line. Yet risks persist in forward-looking impacts on revenues.
8-K
ATM offering activated
Vivos Therapeutics activated its at-the-market offering on September 12, 2025, enabling sales of up to $5.8 million in common stock through H.C. Wainwright & Co., LLC, under a newly effective shelf registration. No shares have sold yet, but this setup provides flexible capital access amid market volatility. The move bolsters liquidity. Regulatory approval came swiftly, yet execution hinges on favorable conditions.
8-K
Q2 revenue dips on acquisition pivot
Vivos Therapeutics reported Q2 2025 revenue of $3.8 million, down from $4.1 million in 2024, as the company pivots its sales model via the June 10 acquisition of The Sleep Center of Nevada, generating $500,000 in diagnostic revenue over 20 days post-close. Gross margin slipped to 55% amid product mix shifts and integration costs, while operating loss widened to $4.9 million from elevated expenses. Yet patient demand surges, booking appointments weeks out. Forward-looking, Vivos eyes scaling through alliances like the July 14 MISleep deal, but integration risks loom.
10-Q
Q2 FY2025 results
Vivos Therapeutics posted Q2 revenue of $3.8M, down 6% y/y but up 11% q/q (derived), as service revenue dipped from legacy VIP enrollments while product sales held steady amid the pivot to sleep center alliances. Gross margin slipped to 55% from 65% y/y, pressured by higher diagnostic costs, fueling an operating loss of $4.9M versus $1.9M last year; net loss widened to $5.0M or $0.55/share on 9.1M diluted shares, matching the prior quarter's pace. The June acquisition of The Sleep Center of Nevada closed for $8.7M (cash/stock/contingent per Note 3), recognizing $5.6M goodwill and $1.9M intangibles (amortized over 4-8 years), with early $0.5M revenue contribution signaling integration momentum. Cash ended at $4.4M after $7.3M operating burn, offset by $11.5M financing inflows including $9.6M debt at 9%; free cash flow not disclosed in the 10-Q. SCN's seven Nevada sites now drive higher-margin diagnostics and appliance uptake. Yet regulatory scrutiny on corporate practice of medicine looms large.
INSP
Inspire Medical Systems, Inc.
75.17-2.00
LIVN
LivaNova PLC
53.34-0.52
NYXH
Nyxoah SA
5.09+0.08
PETV
PetVivo Holdings Inc.
1.45-0.04
RDGL
Vivos Inc.
0.08-0.00
RMD
ResMed Inc.
253.62-2.95
RMSL
RemSleep Holdings, Inc.
0.00+0.00
SONX
Sonendo, Inc.
0.26-0.15
VANI
Vivani Medical, Inc.
1.77+0.10
VMD
Viemed Healthcare, Inc.
6.54-0.32